195 related articles for article (PubMed ID: 25343149)
1. An antiemetic for irritable bowel syndrome?
Levy R; Corbo J; Prasad S
J Fam Pract; 2014 Oct; 63(10):600-2. PubMed ID: 25343149
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron and irritable bowel syndrome.
Luthra P; Ford AC
Gut; 2015 Jul; 64(7):1181. PubMed ID: 24846912
[No Abstract] [Full Text] [Related]
3. Revival of 5-HT3 antagonism as treatment of IBS-D?
Barbara G
Gut; 2014 Oct; 63(10):1530-2. PubMed ID: 24465028
[No Abstract] [Full Text] [Related]
4. The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea.
Luthra P; Ford AC
Gastroenterology; 2014 Aug; 147(2):527-8. PubMed ID: 24953627
[No Abstract] [Full Text] [Related]
5. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
Garsed K; Chernova J; Hastings M; Lam C; Marciani L; Singh G; Henry A; Hall I; Whorwell P; Spiller R
Gut; 2014 Oct; 63(10):1617-25. PubMed ID: 24334242
[TBL] [Abstract][Full Text] [Related]
6. Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging.
Marciani L; Wright J; Foley S; Hoad CL; Totman JJ; Bush D; Hartley C; Armstrong A; Manby P; Blackshaw E; Perkins AC; Gowland PA; Spiller RC
Aliment Pharmacol Ther; 2010 Sep; 32(5):655-63. PubMed ID: 20626735
[TBL] [Abstract][Full Text] [Related]
7. Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?
Stacher G
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):15-27. PubMed ID: 19072430
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological and clinical profile of ramosetron hydrochloride (Irribow), a novel therapeutic agent for irritable bowel syndrome with diarrhea].
Hirata T; Funatsu T; Keto Y; Akuzawa S; Akiho H; Nishida A; Sasamata M; Miyata K
Nihon Yakurigaku Zasshi; 2009 May; 133(5):281-91. PubMed ID: 19443966
[No Abstract] [Full Text] [Related]
9. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
Dizdar V; Gilja OH; Hausken T
Neurogastroenterol Motil; 2007 Dec; 19(12):977-82. PubMed ID: 17973637
[TBL] [Abstract][Full Text] [Related]
10. Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation?
Melchior C; Simrén M
Am J Gastroenterol; 2020 Dec; 115(12):1976-1978. PubMed ID: 33079746
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea.
Black CJ; Ford AC
Am J Gastroenterol; 2021 Feb; 116(2):428-429. PubMed ID: 33177346
[No Abstract] [Full Text] [Related]
12. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
Lewis JH
Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
[TBL] [Abstract][Full Text] [Related]
13. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Hayashi K; Akiho H; Nakashima Y; Haruma K
J Gastroenterol; 2016 Sep; 51(9):874-82. PubMed ID: 26800997
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
15. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
Bellini M; Rappelli L; Blandizzi C; Costa F; Stasi C; Colucci R; Giannaccini G; Marazziti D; Betti L; Baroni S; Mumolo MG; Marchi S; Del Tacca M
Am J Gastroenterol; 2003 Dec; 98(12):2705-11. PubMed ID: 14687821
[TBL] [Abstract][Full Text] [Related]
16. Ondansetron for diarrhea associated with neuroendocrine tumors.
Kiesewetter B; Raderer M
N Engl J Med; 2013 May; 368(20):1947-8. PubMed ID: 23675671
[No Abstract] [Full Text] [Related]
17. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
Moskwa A; Boznańska P
Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
[TBL] [Abstract][Full Text] [Related]
18. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Qi Q; Zhang Y; Chen F; Zuo X; Li Y
BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
[TBL] [Abstract][Full Text] [Related]
19. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work.
Schoenfeld P
Gastroenterol Clin North Am; 2005 Jun; 34(2):319-35, viii. PubMed ID: 15862938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
